ReviewClinical & developmental immunology2012
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between cytotoxic T lymphocyte antigen-4 +49A/G, -1722T/C, and -1661A/G polymorphisms and cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer.BMC gastroenterology · 2024Article
- NK Cell-Based Immunotherapies in Cancer.Immune network · 2020Review
- Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms.Frontiers in oncology · 2020Review
- Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.Experimental & molecular medicine · 2018Review
- High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4Frontiers in oncology · 2018Article
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.Cancer cell · 2017Article
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.Translational cancer research · 2016Article
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.Journal of the National Cancer Institute · 2016Review
- Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.Breast care (Basel, Switzerland) · 2016Review
- CAR therapy: the CD19 paradigm.The Journal of clinical investigation · 2015Review
- Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.World journal of stem cells · 2015Review
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Frontiers in oncology · 2015Review
- The importance of animal models in tumor immunity and immunotherapy.Current opinion in genetics & development · 2014Review
- Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.The Journal of steroid biochemistry and molecular biology · 2013Review
- Delayed presentation of melanoma-associated retinopathy and subsequent resolution with cytoreduction surgery.Documenta ophthalmologica. Advances in ophthalmology · 2013Article
- Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.Cancer immunology, immunotherapy : CII · 2013Article
- The basic principles of chimeric antigen receptor design.Cancer discovery · 2013Review
- Therapeutic cancer vaccines: past, present, and future.Advances in cancer research · 2013Review
- Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion.Journal of oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) ipilimumab for advanced melanoma. In addition, the clinical evaluations of a variety of promising immunotherapy drugs are well under way. Benefiting from more efficacious immunotherapeutic agents and treatment strategies, a number of recent clinical studies have achieved unprecedented therapeutic outcomes in some patients with certain types of cancers. Despite these advances, however, the efficacy of most cancer immunotherapies currently under clinical development has been modest. A recurring scenario is that therapeutic maneuvers initially led to measurable antitumor immune responses in cancer patients but ultimately failed to improve patient outcomes. It is increasingly recognized that tumor cells can antagonize therapy-induced immune attacks through a variety of counterregulation mechanisms, which represent a fundamental barrier to the success of cancer immunotherapy. Herein we summarize the findings from some recent preclinical and clinical studies, focusing on how tumor cells advance their survival and expansion by hijacking therapy-induced immune effector mechanisms that would otherwise mediate their destruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.